1. Home
  2. AIMD
  3. Earnings

AI Earnings Predictions for Ainos Inc. (AIMD)

Machine learning predictions based on historical earnings data and price patterns

Latest Prediction

SELL

1-Day Prediction

-2.28%

$1.11

0% positive prob.

5-Day Prediction

-11.93%

$1.00

0% positive prob.

20-Day Prediction

-7.20%

$1.05

0% positive prob.

Price at prediction: $1.14 Confidence: 100.0% Model AUC: 1.0000 Quarter: Q3 2026

Historical Earnings Predictions

Quarter Signal 1D Return 5D Return 20D Return Confidence Actual 5D
Q3 2026 SELL -2.28% -11.93% -7.20% 100.0% Pending
Q2 2026 SELL -2.17% -12.36% -9.57% 100.0% -1.38%

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 16, 2026 · 100% conf.

AI Prediction SELL

1D

-2.28%

$1.11

Act: +7.58%

5D

-11.93%

$1.00

20D

-7.20%

$1.05

Price: $1.14 Prob +5D: 0% AUC: 1.000
0001493152-26-052061

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum

Q3 revenue rises 29,567% year over year to $642,889; GAAP net loss narrows 36%

$9 million follow-on AI Nose order expands semiconductor relationship; $4.5 million initial payment due within 60 days of signing

$175,000 in quarterly recurring revenue expected beginning in Q4 from the initial AI Nose deployment

Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos” or the “Company”) today announced financial results for the third quarter ended September 30, 2026, highlighting increased revenue, a narrower net loss and progress in AI Nose semiconductor commercialization and VELDONA licensing. Subsequent to quarter-end, the Company secured an additional $9 million AI Nose order with $4.5 million initial payment due in 60 days, and collected $950,000 contractual payments.

Eddy Tsai, Chairman, President and Chief Executive Officer, commented:

“Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by VELDONA licensing and our AI Nose semiconductor program. We delivered 1,400 AI Nose systems under our initial $2.1 million agreement and received initial orders from another semiconductor customer.”

“Following quarter-end, our existing backend semiconductor customer signed a $9 million purchase agreement for 5,000 additional AI Nose systems—more than four times the value of the initial agreement. We believe this follow-on order is tangible evidence of customer demand for Chemical Intelligence in semiconductor manufacturing. As we execute the agreement and collect contractual payments, we expect it to support revenue growth and strengthen working capital.”

“Our focus is on fulfilling customer commitments, expanding recurring services and directing operating resources toward Chemical Intelligence commercialization. Our chemical dataset grew from more than 1 billion records in September to over 3 billion in October, supporting product refinement and broader applications. Our potential $10 million VELDONA licensing framework provides a partner-funded path for assigned clinical and regulatory development while we retain core platform ownership.”

Christopher Lee, Chief Financial Officer of Ainos, added:

“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%. GAAP gross margin increased to 83.4% from 78.0% in the third quarter of 2025, while non-GAAP gross margin increased to 83.6% from 78.0%, excluding share-based compensation and depreciation and amortization allocated to cost of revenue. GAAP operating expense declined 20.3% year over year. These improvements benefited from the recognition of the one-time $600,000 initial VELDONA license fee and revenue from AI Nose semiconductor programs.”

“Beginning in Q4 2026, we expect the $2.1 million AI Nose agreement to contribute approximately $175,000 in recurring revenue per quarter over the three-year service period, providing a more predictable revenue foundation.”

“Following quarter-end, we collected $950,000 from the VELDONA license payment and AI Nose semiconductor commercialization. The $9 million follow-on AI Nose agreement provides for a $4.5 million initial payment within 60 days of signing. We have also begun discussions to address convertible-notes due in 2027. We believe these efforts will strengthen our working capital foundation and support the next phase of order execution.”

Q3 2026 Highlights

●Delivered 1,400 AI Nose systems to backend semiconductor customer under the $2.1 million, three-year subscription services; expecting $175,000 revenues per quarter beginning Q4 2026 over the service period.

●Received initial orders from a front-end semiconductor customer.

●Introduced second-generation AI Nose, with software and hardware upgrades designed for continuous sensing in industrial environment.

●Surpassed 1 billion real-world chemical records, strengthening the data foundation for model development and application-specific validation.

●Secured three Japanese patents covering AI Nose technologies and their integration with robotic systems.

●Established a potential $10 million VELDONA licensing framework for two initial indications and conditional additional licensing opportunities. The partner funds assigned clinical and regulatory development; Ainos retains core platform ownership and participation in applicable net sublicensing revenue.

●Completed VELDONA technology transfer, triggering the $600,000 initial license fee recognized in Q3 and collected after quarter-end.

●Launched Atmosphere Engine, a modular platform designed to generate nitrogen and oxygen from ambient air near the point of use for semiconductor and AI infrastructure applications.

●Improved financial performance: Q3 2026 revenue rose

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 3, 2026 · 100% conf.

AI Prediction SELL

1D

-2.17%

$1.42

Act: -2.76%

5D

-12.36%

$1.27

Act: -1.38%

20D

-9.57%

$1.31

Price: $1.45 Prob +5D: 0% AUC: 1.000
0001493152-26-035859

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets

Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) (“Ainos” or the “Company”) today announced results for the second quarter ended June 30, 2026, and provided a business update on continued execution progress for AI Nose across semiconductor manufacturing, industrial infrastructure, robotics, and healthcare-related environments.

Eddy Tsai, Chairman, President and Chief Executive Officer, commented:

“We believe AI is increasingly expanding beyond understanding text, images, and speech toward interpreting real-world environmental information. This vision continues to guide Ainos’ commercialization strategy for AI Nose. We believe future semiconductor manufacturing, industrial infrastructure, healthcare environments, and robotics applications will increasingly require intelligent environmental awareness, and AI Nose continues to advance steadily toward that objective.”

“During the first half of 2026, we continued executing our commercialization roadmap by expanding AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and robotics environments. I believe these deployments not only support commercial applications, but also continuously expand our real-world environmental dataset, strengthen our Smell ID dataset, and enhance the learning and environmental pattern recognition capabilities of our Smell Language Model (SLM), enabling our Smell AI Platform to continue evolving.”

“Since December 2025, AI Nose has accumulated approximately 613 million industrial smell data records, primarily from semiconductor manufacturing environments. We believe these growing real-world datasets represent an important foundation for the long-term development of Smell AI. We believe every new deployment expands application opportunities while further strengthening our platform’s ability to recognize and understand diverse environmental patterns, allowing our Smell AI Platform to continuously learn and evolve through real-world experience.”

“We are encouraged by the progress of our commercialization activities. As existing deployments continue to advance, strategic collaborations expand, and additional real-world data strengthens the platform, we remain focused on executing our commercialization strategy, expanding real-world applications, and steadily advancing the long-term development of our Smell AI Platform.”

Christopher Lee, Chief Financial Officer of Ainos, added, “Our second-quarter results reflect Ainos’ continued execution of its commercialization strategy. We are focused on supporting AI Nose deployments across semiconductor manufacturing, industrial infrastructure, healthcare, and other real-world environments while advancing commercialization initiatives and expanding strategic collaborations that strengthen the Company’s long-term foundation. We continue to believe our activities will help support broader revenue generation opportunities in the second half of 2026.”

Mr. Lee continued, “We remain committed to disciplined capital allocation and financial management while supporting our core commercialization strategy, technology development, and deployment priorities. We will continue focusing on operational efficiency, strategic deployment activities, and financial discipline as we execute our long-term commercialization strategy.”

Second Quarter 2026 and Recent Operational Highlights

● Advanced deployments associated with the previously announced initial $2.1 million commercial arrangement in backend semiconductor manufacturing environments.

● Continued pilot programs in selected front-end semiconductor environments.

● Expanded AI Nose deployment and validation activities across industrial and healthcare infrastructure environments, including facility monitoring, safety, ventilation, equipment, and chemical handling applications.

● Expanded research activities involving emergency care environments and exhaled breath pattern analysis.

● Continued robotics-related pilot and deployment activities.

● Supported use-case expansion through channel and integration partnerships.

● Continued development of Smell ID datasets and smell language model capabilities using deployment and pilot data.

Ainos is focused on execution, deployment, Smell ID dataset expansion, smell language model development, and strategic commercial expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. S

2026
Q1

Q1 2026 Earnings

8-K

May 13, 2026

0001493152-26-022751

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Ainos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets

HOUSTON,

TX / ACCESS Newswire / May 13, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) (“Ainos” or the “Company”) today announced financial results for the first quarter ended March 31, 2026 and provided a business update on recent execution progress for AI Nose across semiconductors and healthcare infrastructure applications.

During the first quarter of 2026, Ainos continued executing its commercialization priorities for AI Nose across industrial infrastructure environments while continuing to expand its Smell ID datasets and refine its Smell Language Model (“SLM”) through deployment and pilot activities.

“Our first quarter progress reflects a continued transition from validation activities toward broader enterprise-level infrastructure deployment readiness,” said Eddy Tsai, Chairman, President and CEO of Ainos. “We believe the operational milestones achieved during the quarter has strengthened the foundation for future scalable commercialization of Smell AI – powered by AI Nose.”

“In addition to our progress in semiconductor environments, we are expanding AI Nose deployment into healthcare infrastructure settings, including hospital utility systems, laboratory environments, HVAC-related monitoring, MRI-related environments, and critical infrastructure safety applications. We believe this represents an important long-term application category for AI-driven environmental intelligence, by enabling continuous monitoring, anomaly awareness, and operational stability for hospital operation,” Mr. Tsai concluded.

Christopher Lee, Chief Financial Officer of Ainos, added, “During the first quarter, we strengthened our balance sheet and liquidity position through the previously announced NT$90 million (approximately US$2.8 million) financing arrangement while maintaining operating discipline as we advanced commercialization activities. Reported operating expenses declined approximately 30% year-over-year to approximately US$2.28 million.”

“Revenue during the quarter reflected the Company’s ongoing transition toward industrial and infrastructure-focused AI Nose deployments, which remain in earlier stages of commercialization and validation. We believe our current execution priorities will help support broader revenue generation opportunities in the second half of 2026,” Mr. Lee added.

First Quarter 2026 and Recent Operational Highlights

● Continued deployment activities associated with the previously announced approximately three-year $2.1 million AI Nose commercial arrangement in backend semiconductor manufacturing environments, targeting approximately 1400 AI Nose systems

● Initiated pilot and validation activities in selected front-end semiconductor environments

● Expanded industrial commercialization initiatives through a distribution partnership supporting front-end semiconductor opportunities

● Continued robotics integration and pilot activities involving robotic and quadruped systems

● Continued development of Smell ID datasets and Smell Language Model capabilities through deployment and pilot activities

● Continued optimization of AI Nose’s near-threshold sensing and pattern-recognition capabilities through ongoing deployment and validation activities, supporting earlier identification of environmental anomalies across customer environments

The Company believes that enterprise adoption of AI-driven environmental intelligence technologies is typically driven by structured implementation roadmap with phased validation, infrastructure integration, and staged deployment. Ainos is aligning its commercialization strategy with these anticipated enterprise adoption patterns as it advances AI Nose across semiconductor, healthcare infrastructure, robotics, and industrial markets.

Ainos remains focused on execution, deployment readiness, Smell ID dataset expansion, Smell Language Model development, and strategic commercial expansion, supporting its long-term objective of advancing AI Nose as a scalable Smell AI platform for real-world infrastructure environments.

About AI Nose

AI Nose digitizes scent into Smell ID, an AI-driven form of scent intelligence. The full-stack electronic nose platform integrates high-precision MEMS sensor arrays with proprietary AI algorithms designed to support ppb-level scent detection sensitivity, subject to application conditions and deployment configurations. Smell ID converts analog scent signals into structured, actionable data, while the proprietary Smell Language Model (SLM) is designed to learn, classify, and contextualize complex scent patterns over time.

Built upon more than a decade of accumulated scent data and deep medtech expertise, AI Nose is designed to support continuous monitoring, predictive analysis, and real-time alerts across industrial and manufacturing environments. AI No

About Ainos Inc. (AIMD) Earnings

This page provides Ainos Inc. (AIMD) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.

Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on AIMD's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.

Share on Social Networks: